Category: Medical
-
STAT+: Up and down the ladder: The latest comings and goings
•
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with…
-
STAT+: Grail CEO steps down after trial setback
•
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
-
STAT+: Pharmalittle: We’re reading about Trump and drug prices, biotechs pushing back, and more
•
And so, another working week will soon draw to a close. Not a moment too soon, yes? This…
-
STAT+: Trump is getting more credit than Biden for efforts to lower drug prices
•
WASHINGTON — Reining in drug prices has been a priority for both the Trump and Biden administrations. Trump…
-
STAT+: FDA launches unified system for adverse event reports
•
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
-
Analysis of Medicare data shows who mental health providers treat over telehealth
•
In today’s edition, important questions about the rapid adoption of health technology. Who is responsible, how is it…
-
STAT+: Pharmalittle: We’re reading about telehealth prescribers, a Lilly push against compounding, and more
•
Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the incredibly…
-
STAT+: FDA approves leucovorin for rare disorder without trial data
•
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
-
STAT+: Pharmalittle: We’re reading about the FDA warning Novo Nordisk, Lilly investing in China, and more
•
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far. It is…
-
STAT+: GOP senator is investigating the FDA over rejections of rare disease drugs
•
WASHINGTON — Sen. Ron Johnson (R-Wis.) said he is investigating the Food and Drug Administration’s rejections of rare disease…
-
STAT+: What’s next for RFK Jr.’s MAHA allies on vaccine policy?
•
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health…
-
Statins don’t cause most of the side effects on package warnings, study finds
•
Far fewer people who could benefit from statins actually take the cholesterol-lowering drugs now. Many who start taking…
-
STAT+: Novo Nordisk accuses Hims & Hers of ‘illegal mass compounding’ over a cheaper version of Wegovy pill
•
In an unexpected move, Hims & Hers is making available a cheaper, compounded version of the Wegovy weight…
-
What to know about TrumpRx, the Trump administration’s prescription drug platform
•
President Trump on Thursday night is planning to announce the launch of TrumpRx, the website that he and…
-
STAT+: Novo and Lilly both see price cuts as helpful for long-term gain
•
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
-
STAT+: Pharmalittle: We’re reading about Super Bowl drug ads, an FTC deal with Express Scripts, and more
•
Rise and shine, everyone, another busy day is on the way. This morning is getting off to a…
Recent Posts
- It’s bracket time: Make your picks for the men’s tournament
- Men’s March Madness 2026 bracket: Get to know all 68 teams
- Mets’ Lindor has hit in post-surgery spring debut
- Boilermakers trip No. 3 Michigan, reign in Big Ten
- Young birdies 17, wins Players on Fitzpatrick miss
- Duke, Arizona, Michigan, UF top seeds in NCAAs
- Sabalenka outlasts Rybakina for Indian Wells title
- Oscars red carpet: Stars and fashion in pictures
- Kelly and Mark preview ‘After the Oscars Show’ on the red carpet
- 2026 NCAA Men’s Basketball Tournament selections revealed
- Pope escalates call for ceasefire in Iran by addressing those responsible for the war
- Veteran ’60 Minutes’ reporter says the network ‘crumbled’ under Trump’s pressure
Social Media
Advertisement
